Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a β2-adrenergic agonist used to inhibit uterine contractions of premature labor. Administration by intravenous infusion or repeated intramuscular injections for a maximum of 2 days.
Since the last update we have not found published data on its excretion in breastmilk.
Its very large volume of distribution can make it difficult to pass into breast milk.
Its very low oral bioavailability minimizes the passage into plasma of the infant from ingested breast milk.
Although temporary cessation of breastfeeding should be considered when a woman is experiencing premature labor, breastfeeding during pregnancy does not increase the risk of premature labor and birth. (Ayrim 2014)
Monitor possible appearance of tachycardia, hypotension, fever, irritability or tremors in the infant. Until published data on this drug in relation to lactation are known, known safer alternatives are preferable.